57 results about "Islet cells" patented technology

The invention provides a stem cell exosome vesicle induced by traditional Chinese medicine functional components as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. According to the preparation method of the stem cell exosome vesicle, traditional Chinese medicine functional components serve as an exosome inducer, stem cells can be induced to proliferate and secrete exosome with the enhanced function, the yield of the exosome can be increased, bioactive molecules can be loaded, and the bioavailability of the exosome in diabetes treatment is remarkably improved. The stem cell exosome vesicle disclosed by the invention can be applied to treatment of diabetes and complications thereof, not only can improve functions of islet cells, but also can treat chronic inflammation, microangiopathy and other metabolic diseases related to diabetes, and has a wide clinical application prospect.

The invention provides a pancreatic islet organ capable of efficiently maintaining pancreatic islet beta cell identity and a preparation method and application thereof. Specifically, the invention provides the preparation method for the in-vitro pancreatic islet organ, and the preparation method comprises the following steps: carrying out induced differentiation culture on the ZnT8-knocked-out pluripotent stem cells, so as to obtain the mature pancreatic islet organ. The invention also provides a corresponding transplantation composition and application thereof. The invention discloses that ZnT8 knockout is a key factor for effectively maintaining the identity stability of beta cells in pancreatic islet organs. In addition, the pancreas islet beta cell identity maintenance agent is combined with the ZnT8-knocked-out pancreas islet organ for use, so that the identity stability of the pancreas islet organ beta cell can be obviously maintained. The invention provides a new strategy for transplantation treatment of type 2 diabetes, and has excellent clinical transformation value.

The invention provides a composition for treating diabetes as well as a preparation method and application thereof, and belongs to the technical field of medicines. The preparation method comprises the following steps: loading berberine on a milk exosome to prepare a berberine-loaded exosome, loading liraglutide on phycobiliprotein to prepare liraglutide-loaded phycobiliprotein, preparing PEG-COOH, reacting with chitosan to prepare a chitosan-polyethylene glycol graft polymer, embedding the berberine-loaded exosome and the liraglutide-loaded phycobiliprotein, and cross-linking to prepare microspheres. And centrifuging, washing and drying to obtain the composition for treating diabetes. According to the prepared composition for treating diabetes, the loading capacity of the medicine is greatly improved, the carrier also has a very good protection effect on islet cells, so that islet cell injury is repaired, normal insulin secretion of islet cells is promoted, the prepared composition can be orally taken, the medicine effect is greatly improved, the compliance of patients is improved, and the preparation method is suitable for clinical application. The bioavailability is high, and safety and non-toxicity are realized.

The invention relates to the technical field of medicines, in particular to application of a recombinant protein DEL-1 in preparation of a medicine for resisting pancreatic beta cell senescence. Within the concentration range of 400-1000 ng / ml, the DEL-1 can reduce the high glucose and high fat induced pancreatic beta cell SA-beta-Gal positive rate by 39.5% or above, and the anti-aging effect is remarkable.

While there have been reports of cultivating islet-like insulin-producing cells by inducing differentiation of ES / iPS cells, the technology for cultivating high-functioning, large-scale insulin-positive islet cells is not yet mature, and there are concerns about rejection and unexpected immune responses. The present invention provides islet-like cells into which the Mycl gene has been introduced, as well as methods for inducing the proliferation of islet-like cells and their differentiation into insulin-producing cells through transient expression of the Mycl gene.

This invention is applied in the field of medicine, namely in endocrinology, and can be used in the treatment of type 1 diabetes. The invention proposes a combination containing a dipeptidyl peptidase 4 (DPP-4) inhibitor, a proton pump inhibitor (PP1), and γ-aminobutyric acid or γ-aminobutyric acid receptor agonist. This unique combination and dosage of drugs leads to the regeneration (recovery) of pancreatic β-cells, which occurs with a dramatic reduction in insulin requirements up to a total cessation of insulin in some individuals and is intended for the treatment of type 1 diabetes mellitus.

The utility model relates to the technical field of preserving fluid bottles, in particular to a preserving fluid bottle for islet cells, which comprises a bottle body, a bottle cap is screwed at the top end of the bottle body, a plug is integrally formed on the surface of the bottle cap, a rubber cover is fixed inside the plug, an elastic band ring is fixed at one end of the rubber cover, and after the rubber cover is turned outwards and sleeved on the outer side of the bottle body, the elastic band ring is fixed at the other end of the rubber cover. The elastic band ring is positioned below the bottle body; the preserving fluid bottle for the islet cells has the advantages that due to the design of the rubber cover, the rubber cover can be contained between the chock plug and the baffle when the preserving fluid bottle is not used, the rubber cover can be turned outwards to be arranged on the outer side of the bottle body in a sleeving mode, the shading effect is achieved, and the islet cells are protected against light damage. After the rubber cover is turned outwards and arranged on the outer side of the bottle body in a sleeving mode, the anti-collision capacity of the bottle body can be improved, and the bottle body is prevented from being damaged due to collision in the transportation or storage process. Due to the design of the elastic band ring, the rubber cover can be firmly fixed to the bottle body and is not prone to falling off, and meanwhile a user can conveniently take down or sleeve the rubber cover at any time according to needs.

The invention belongs to the technical field of polypeptide preparation and biological medicine, and particularly relates to a preparation method of Jingzhaotoxin polypeptide IX (JZTX-IX) and application of Jingzhaotoxin polypeptide IX in treatment of diabetes mellitus. A chilobrachys jingzhao toxin polypeptide IX coding gene, a 6 * His tag nucleotide sequence, a thrombin restriction enzyme cutting site nucleotide sequence and an MBP hydrotropy tag nucleotide sequence are connected to a prokaryotic expression vector for prokaryotic expression, and the expressed polypeptide is purified to obtain the chilobrachys jingzhao toxin polypeptide IX protein. The target polypeptide with high purity, complete disulfide bond folding and uniform conformation is obtained, so that the high purity and biological activity of the target polypeptide are ensured. On the basis, the treatment activity of the JZTX-IX on diabetes mellitus especially type II diabetes mellitus is found and verified, and the JZTX-IX can remarkably reduce fasting blood glucose of mice with the type II diabetes mellitus, improve glucose tolerance and insulin sensitivity, relieve polydipsia and polyuria symptoms and promote insulin secretion and islet cell proliferation.

The application discloses a temperature-sensitive hydrogel with a diabetes treatment effect, a kit, a use method and application thereof, and belongs to the technical field of diabetes treatment drugs. The temperature-sensitive hydrogel is formed by mixing a human umbilical vein endothelial cell suspension, a mixed solution with a final concentration of 15-20% of P407 and a final concentration of 0.6-0.8% of sodium hyaluronate, a final concentration of 50 ng / mL of vascular endothelial growth factor, a final concentration of 10 ng / mL of basic fibroblast growth factor, a final concentration of 0.5-2% of lidocaine hydrochloride, a final concentration of 100-200 mg / mL of tumor necrosis factor alpha monoclonal antibody and a final concentration of 2-5% of islet cell-alginic acid gel fiber segments with a length of less than 1 mm. The temperature-sensitive hydrogel is safe, non-toxic, low in immunogenicity, low in cost and good in treatment effect. The reagent is combined with sterile consumables to form a kit, and the kit is convenient to use and can be better applied to the treatment of diabetes.

The invention discloses a compound polysaccharide preparation for treating diabetes and application thereof, and belongs to the technical field of biomedicine. The compound polysaccharide preparation is composed of compound polysaccharide A and compound polysaccharide B according to the mass ratio of 1: 1. The compound polysaccharide A is prepared from abelmoschus esculentus and chlorella through alkaline ultrasonic extraction and 10-100kDa ultrafiltration classification; the compound polysaccharide B is prepared by performing enzymolysis and hot water extraction on grifola frondosa and sarcodon aspratus. Experiments prove that the preparation can significantly improve insulin secretion and glucose uptake ability of islet cells, effectively reduce fasting blood-glucose of type 2 diabetes model mice and synchronously improve triglyceride and total cholesterol levels through strong synergistic interaction among the components. The preparation disclosed by the invention is natural in source, safe and efficient, so that a new choice is provided for medicine development of type 2 diabetes mellitus.

The invention belongs to the technical field of polypeptide preparation and biological medicine, and particularly relates to a preparation method of Jingzhaotoxin polypeptide XI (JZTX-XI) and application of Jingzhaotoxin polypeptide XI (JZTX-XI) in treatment of diabetes mellitus. A Jingzhaotoxin polypeptide XI coding gene, a nucleotide sequence of a 6 * His tag, a nucleotide sequence of a thrombin restriction enzyme cutting site and a nucleotide sequence of an MBP hydrotropy tag are connected to a prokaryotic expression vector for prokaryotic expression, and a target polypeptide which is high in purity, complete in disulfide bond folding and uniform in conformation is obtained through purification. The purity and the biological activity are relatively high. Meanwhile, the treatment activity of the JZTX-XI in the aspect of diabetes is verified, and it is found that the JZTX-XI can remarkably reduce fasting blood glucose of mice with type II diabetes, remarkably up-regulate a glucose transport regulation gene Glut2, improve glucose tolerance and insulin sensitivity, relieve polydipsia and polyuria symptoms and promote insulin secretion and islet cell proliferation.

The invention discloses application of tacrolimus in preparation of a medicine for treating type 2 diabetes and complications thereof, and belongs to the field of biological medicine. Animal experiments prove that Tacrolimus (TM) can effectively improve type 2 diabetes mellitus and obesity-related abnormal glycolipid metabolism. In addition, the TM can also relieve liver injury caused by diabetes and obesity and improve liver fatty degeneration and abnormal lipid metabolism. What's more important is that toxicity of TM to pancreatic beta cells is not observed in long-term multi-model experiments (including diabetes, obesity and elderly mice). The invention provides an important basis for developing novel diabetes treatment drugs, lays a foundation for expanding new indications of tacrolimus, and has potential clinical transformation value.

The invention relates to the field of biological medicines, in particular to application of a hepatocyte nuclear factor 1 alpha (HNF1 alpha) in promoting beta cell regeneration and preventing and treating diabetes. Specifically, by regulating and controlling the expression of an HNF1alpha coding gene and the activity of HNF1alpha, pancreas islet alpha cells can be promoted to be transdifferentiated into beta cells to achieve beta cell regeneration, the functions of pancreas islet beta cells are reserved, the occurrence of diabetes mellitus is delayed, and a new medical approach is provided for prevention and treatment of diabetes mellitus.

The application discloses a frozen embedding block of islet cell-like cell clusters meeting spatiotemporal omics continuous section analysis, a method and application thereof, and belongs to the field of frozen embedding block preparation. In order to solve the problem of RNA / DNA integrity and visualization of islet cell clusters, the method comprises the following steps: adding a buffer solution containing bromophenol blue drop by drop to the aggregated cell clusters on the inner surface of the bottom of a silk cloth to dye the cell clusters; keeping the selected area of the silk cloth in contact with the frozen embedding reagent surface of the lower half groove in the loading groove of a first mold, placing the first mold on dry ice, and completely freezing the frozen embedding reagent of the lower half groove and the cell clusters on the surface thereof; placing the first mold with the upper half groove frozen embedding reagent added in the loading groove on dry ice, completely freezing the frozen embedding reagent of the upper half groove and the cell clusters on the surface thereof, and making the frozen embedding reagent of the upper half groove and the frozen embedding reagent of the lower half groove be integrated into the frozen embedding block, and taking out the frozen embedding block, wherein the cell clusters are distributed at the middle position on the height of the frozen embedding reagent block.

The invention discloses an application of WBSCR16 protein as a target spot in preparation of a medicine for treating diabetes, and provides an application in research and development of related medicines. By constructing a mouse model of Wbscr16 with pancreatic beta cells specifically knocked out, the action mechanism of WBSCR16 in diabetes mellitus attack is deeply researched, and it is found that WBSCR16 participates in regulating the mitochondrial function of the pancreatic beta cells, and then insulin secretion is affected. On the basis, the invention provides a reagent for regulating the expression of the WBSCR16 protein for treating diabetes mellitus. Meanwhile, a construction method of the Wbscr16 pancreatic beta cell specific knockout mouse model is described in detail, and an important tool is provided for related research. Meanwhile, candidate drugs capable of acting on a WBSCR16 target spot are screened out through drug prediction, and a new strategy and a potential intervention direction are provided for treatment of diabetes mellitus.

The invention discloses a pharmaceutical composition for reducing blood sugar and application thereof, and belongs to the technical field of preparation of drugs for reducing blood sugar. The pharmaceutical composition is prepared from the following components in parts by weight: 5 to 7 parts of empagliflozin, 30 to 40 parts of cortex cinnamomi extract, 500 to 700 parts of metformin, 60 to 80 parts of microcrystalline cellulose, 10 to 15 parts of polyvinylpolypyrrolidone, 100 to 120 parts of HPMC K100M, 50 to 60 parts of ethyl cellulose, 40 to 50 parts of Eudragit FS30D, 40 to 50 parts of soybean phospholipid and 10 to 20 parts of poloxamer 188. The composition is applied to preparation of sustained-release tablets for reducing blood sugar, and can reduce loss of islet cells and protect kidney functions and gastric mucosa.

The invention relates to the technical field of cell engineering, in particular to a method for inducing Muse cells to differentiate into pancreatic beta cell spheres through balling / adherent alternate culture and application. Experimental results in the invention show that the Muse cells subjected to static balling culture are obvious in apoptosis due to hypoxia in spheres, and almost all the cells are apoptotic after being cultured for 23 days; the Muse cells subjected to direct adherent induction culture are high in proliferation capacity, and the differentiation efficiency is 37.7%; a balling and adherent alternate culture induction mode is adopted, so that stable passage can be realized, and the differentiation efficiency is 62.4%; the alternative culture induction method effectively solves the problems of proliferation and differentiation efficiency, and realizes stable passage and induced differentiation of the pancreatic beta cells.

The present application provides a traditional Chinese medicine composition with blood sugar lowering efficacy and a preparation method thereof, and belongs to the technical field of traditional Chinese medicines; the traditional Chinese medicine composition is prepared from the following raw materials in parts by mass: birch juice 140-200 parts, jujube fruit 20-40 parts, rehmannia 20-40 parts, adenosma 18-26 parts, periploca 18-26 parts, ophiopogon 18-26 parts, bamboo shavings 12-19 parts, leech 12-19 parts, psyllium 12-19 parts, dogwood 10-14 parts, gordon euryale seed 10-14 parts. In the traditional Chinese medicine composition, the blood sugar lowering effect is mainly achieved by repairing the function of islet beta cells, promoting the regeneration of islet beta cells, improving sugar metabolism, increasing the sensitivity of insulin or improving insulin resistance, so that the overall prescription achieves the effects of invigorating the spleen and lung, nourishing yin and reducing fire, benefiting the stomach and producing saliva, astringing the spleen essence, promoting transportation and transformation, tonifying the kidney and strengthening the body, and relieving polydipsia and restlessness.

Provided are preparation methods for an islet extracellular matrix scaffold and a biomimetic islet organoid. The scaffold is a gel, and the gel contains 3-5 mg / mL Collagen I, 3-5 mg / mL Collagen IV, and 0.8-1.2 mg / mL Laminin. For the scaffold, Collagen I, Collagen IV, and Laminin are simultaneously selected as extracellular matrix components, which have relatively strong interactions with islet cells, and effectively promote the islet cells and enhance insulin secretion function stimulated by glucose after binding to the islet cells. Collagen VI can also be used. Collagen VI can act on the islet cells to effectively enhance the survival of the islet cells and the insulin secretion function stimulated by glucose. The gel can form a relatively intact network structure without needing to use a cross-linking agent, thereby enhancing the support capacity for the islet organoid.

The invention provides a pharmaceutical composition helpful for reducing blood glucose as well as a preparation and application thereof, and relates to the field of medicines. The pharmaceutical composition helpful for reducing blood glucose comprises the following raw materials in parts by weight: 15-20 parts of pomegranate, 8-13 parts of turmeric, 1-2 parts of bear gall, 1-2 parts of schisandra chinensis, 10-15 parts of dendrobe, 5-10 parts of folium eriobotryae, 8-12 parts of radix puerariae, 5-10 parts of dandelion, 8-15 parts of herba epimedii, 8-12 parts of polygonum cuspidatum, 5-8 parts of gynostemma pentaphyllum, 4-8 parts of inula flower and 3-5 parts of cortex lycii radicis. The pharmaceutical composition disclosed by the invention effectively inhibits sugar absorption of intestinal tracts, enhances insulin sensitivity, improves insulin resistance, promotes activity of glucose transporter protein, regulates glycolipid metabolism balance, inhibits liver glycogen decomposition to reduce liver glucose output and reduces interference of inflammatory factors on insulin signal channels through a multi-channel synergistic effect; therefore, the whole metabolic regulation is optimized, the blood sugar level is remarkably reduced, the number of pancreatic beta cells is increased, and the compound can be applied to preparation of drugs for treating diabetes.

The invention discloses a mulberry leaf fermentation composition helpful for reversing insulin resistance and a preparation method thereof, relates to the technical field of mulberry leaf fermentation treatment, and solves the problem that in the prior art, a technology for preparing auxiliary materials for assisting diabetes treatment from mulberry leaves and related products do not exist. The mulberry leaf fermentation composition is prepared from a mulberry leaf extract, a highland barley extract, a bitter gourd extract, hawthorn powder, yam flour, lemon powder, fructo-oligosaccharide, water-soluble dietary fibers, resistant dextrin and a fermentation microbial preparation, wherein the highland barley extract is prepared by mixing a highland barley flavone extract and a highland barley polysaccharide extract according to a mass ratio of (4-6): 1. Through multi-channel combination of'inhibiting sugar absorption, enhancing insulin signals, protecting islet cells and improving metabolism ', insulin signal channels can be effectively improved, inflammatory oxidative stress can be relieved, glucose and lipid metabolism disorder can be regulated, and insulin resistance can be reversed.

The present application discloses the use of SUR2 receptor modulators. In the present application, SUR2 receptor modulators (e.g. MLC1) can be combined with skeletal muscle cell K ATP SUR2 specific binding on potassium ion channel, thus enhancing intracellular calcium signal, increasing glucose uptake of skeletal muscle cell and reducing blood glucose, and thus can be used as a therapeutic drug for diabetes; SUR2 receptor modulators selectively bind to SUR2 through a non-islet β cell dependent mechanism, and have no inhibitory effect on islet β cell SUR1 receptor, and thus can effectively avoid hypoglycemia while reducing blood glucose, and have small side effects.

Provided herein are methods related to delivery of stem cell-derived cell therapies, including stem cell derived islet cell therapies, and related compositions, uses and articles of manufacture. In particular embodiments, the methods relate administering stem cell-derived islet cells. In some embodiments, the subject has a beta cell related disorder, such as diabetes (e.g. Type I diabetes).

The invention discloses nutrition powder capable of reducing blood sugar and preventing diabetic complications and a preparation method of the nutrition powder. The nutrition powder comprises the following components in parts by weight: 20-45 parts of tartary buckwheat flour, 15-35 parts of highland barley flour, 1-8 parts of psyllium husk powder, 1-5 parts of oat beta-glucan, 1-4 parts of inulin, 0.2-1 part of aspartame, 10-25 parts of medicinal and edible food powder and 1-15 parts of medicinal and edible plant extract. Through reasonable compatibility of the tartary buckwheat, the highland barley, the oat beta-glucan, the inulin, the medicinal and edible food, the medicinal and edible food extract and the psyllium seed husk powder, a diabetic patient can have satiety, the intake of food is reduced, the postprandial blood sugar is balanced, the fasting blood-glucose level of the patient can be reduced, islet cells are favorably repaired, and the diabetes mellitus can be effectively treated. Meanwhile, diabetic complications can be prevented.

The invention relates to the field of stem cell culture, in particular to adiponectin gene modified mesenchymal stem cells as well as a preparation method, a medicine and application thereof. The adiponectin gene modified mesenchymal stem cell provided by the invention can overexpress adiponectin to stimulate islet cells, regulate sugar stimulation response and improve insulin secretion amount. The preparation method of the adiponectin gene modified mesenchymal stem cell provided by the invention is simple, and the prepared adiponectin gene modified mesenchymal stem cell is higher in insulin secretion amount and longer in action time in an INS-1 cell sugar stimulation experiment.

The application discloses a sea cucumber active peptide, a preparation method and a blood glucose reduction application, belongs to the field of biological medicines, and the amino acid sequence of the active peptide is Thr-Ser-Pro-Gly-Leu-Gly-Lys-Gly-Phe. The preparation method comprises the following steps: putting chopped sea cucumbers into a reaction container, adding a compound protease for enzyme hydrolysis; enzyme inactivation and centrifugation are performed, and the supernatant is taken; the supernatant is subjected to ultrafiltration through an ultrafiltration membrane with a molecular weight cut-off of 1000 Da, the obtained filtrate is dried to obtain a sea cucumber oligopeptide powder, and Sephadex G25F gel chromatography column separation and purification and C18 reverse phase chromatography column further purification are performed. Experiments show that the active peptide can relieve STZ-induced pancreatic beta cell damage.

The invention relates to an inonotus obliquus fermentation product and application of the inonotus obliquus fermentation product in hypoglycemic drugs, and belongs to the technical field of inonotus obliquus fermentation products. A component culture medium is prepared from 10-15 parts of plant flour, 3-6 parts of glucose, 0.8-1.2 parts of dipotassium phosphate, 1-2 parts of magnesium sulfate, 5-8 parts of protein peptide, 4-8 parts of agar and 60-80 parts of purified water; the component B culture medium is prepared from the following raw materials in parts by weight: 12-15 parts of plant starch, 2-4 parts of glucose, 1-3 parts of oxytetracycline, 1-3 parts of chloramphenicol, 8-16 parts of sodium hyaluronate and 60-80 parts of purified water. Through the multi-target synergistic effect of improving insulin resistance, protecting islet cells, inhibiting sugar absorption and the like, the hypoglycemic effect is obvious, and the prepared inonotus obliquus fermentation product is simple in process, low in operation difficulty, suitable for industrial production and capable of being applied to the fields of cosmetics, textile industry and medicine.

The present invention relates to glycyrrhizin-glycol chitosan conjugate-coated nanoparticles, islet cells, prepared using same, for transplantation, and an MRI imaging composition comprising same. If transplanted, the islet cells comprising the nanoparticles can suppress a post-transplantation immune response. The present invention can provide islet cells for transplantation that can be transplanted to a certain region by magnetic force induction and can be tracked by MRI.

The disclosure provides uses of anti-CD40 ligand antibodies for immunosuppression in islet cell transplantation in subjects having type 1 diabetes (T1D). The disclosure also provides uses of compounds that block the interaction between CD40 and CD40 ligand, including such anti-CD40 ligand antibodies and antigen binding fragments thereof, for preventing or reducing islet cell allograft rejection in subjects having T1D, for restoring physiological insulin secretion or hypoglycemia awareness in a subject having T1D, or for treating subjects having T1D and / or treating subjects having T1D and partial graft function of islet cells where the subjects have had a previous allogenic islet cell transplant.

The application provides a construction method of a zebrafish model of diabetic cerebral hemorrhage sequelae for high-throughput drug screening, and belongs to the technical field of biotechnology.The first zebrafish model capable of comprehensively simulating the complex pathological phenotypes of clinical diabetic cerebral hemorrhage sequelae is successfully constructed, and the blank of the research model in the field is filled.The pathological changes of the model are highly consistent with the symptoms of the patients with clinical diabetic cerebral hemorrhage sequelae, such as glucose metabolism disorder, pancreatic beta cell damage, cerebral vascular injury and hemorrhage, brain cell apoptosis, inflammatory reaction and behavior abnormality, and the limitation that the existing single disease model cannot simulate the synergistic pathogenesis of diabetes and cerebral hemorrhage is overcome, so that a reliable experimental animal model is provided for high-throughput screening of active ingredients against the disease.